This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
9/15/2026
Hello, everyone. Thank you for joining us. Welcome to the Bioceres Crop Solutions Fiscal Fourth Quarter and Full Year 2026 Financial Results Conference Call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star 1 to raise your hand. To withdraw your question, press star 1 again. I will now hand the conference over to Paola Savanti, Head of Investor Relations. Paola, please go ahead.
Good morning and thank you. Welcome everybody to Bioservice Crop Solutions' fourth fiscal quarter and full year 2026 earnings conference call. Our prepared remarks today will be led by our Chief Executive Officer, Federico Trucco, and our Chief Financial Officer, Ezequiel Simmermacher. Both of them will be available for the Q&A session following the presentation. During this call, we will be making forward-looking statements. These statements are based on current expectations and assumptions. that are subject to various risks and uncertainties. I refer you to the forward-looking statement section of the earnings release and presentation, as well as the recent filings with the SEC. We assume no obligation to update or revise any forward-looking statements to reflect new or changed circumstances. In today's presentation, we will be making references to certain non-GAAP financial measures. Reconciliations of the non-GAAP measures can be found in earnings press release. The conference call is being webcast and the link is available at our investor relations website. It is now my pleasure to turn over the call to Federico.
Thanks, Paula, and thank you everyone for joining us today. Good morning. Please turn to slide number three for today's highlights. Fiscal 2026 was a challenging year for Vioceres, marked by the ongoing litigation with certain of our creditors and the business consequences emanating from this dispute. Revenues from our continuing operations declined by 18%, with its consequential decline in gross profits and adjusted EBITDA. Excluding changes associated to our new seed business strategy, The decline in revenues has been most significant in our international business. But in Argentina, our commercial operations have mostly stabilized, in part because of the successful reprofiling of our local debt obligations towards the beginning of the fourth quarter. Against that backdrop, our priorities have been to focus the business on our core capabilities, Ezequiel Simmermacher, Jose Roque, Maria Paula Savanti At the same time, the cost actions implemented throughout the year resulted in a materially lower expense base, allowing us to return to positive adjusted EBITDA in the quarter. Ezequiel will now review our financial performance for the quarter and the full year. I will then return to discuss our outlook towards the end of today's call. Ezequiel.
You're reading a preview of the BIOX Q4 2026 earnings call.
Free account.
